Identification of high-risk patients in multiple myeloma using a clonal gene signature

被引：0
|
作者：
Li, Jian-Rong
Wang, Christiana
Cheng, Chao
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-7663
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7663
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients
    Paiva, B.
    Gutierrez, N-C
    Chen, X.
    Vidriales, M-B
    Montalban, M-A
    Rosinol, L.
    Oriol, A.
    Martinez-Lopez, J.
    Mateos, M-V
    Lopez-Corral, L.
    Diaz-Rodriguez, E.
    Perez, J-J
    Fernandez-Redondo, E.
    de Arriba, F.
    Palomera, L.
    Bengoechea, E.
    Terol, M-J
    de Paz, R.
    Martin, A.
    Hernandez, J.
    Orfao, A.
    Lahuerta, J-J
    Blade, J.
    Pandiella, A.
    San Miguel, J-F
    LEUKEMIA, 2012, 26 (08) : 1862 - 1869
  • [42] Clonal plasma cell proportion in the synthetic phase identifies a unique high-risk cohort in multiple myeloma
    Zanwar, Saurabh
    Jevremovic, Dragan
    Kapoor, Prashant
    Olteanu, Horatiu
    Buadi, Francis
    Horna, Pedro
    Gonsalves, Wilson
    Otteson, Gregory
    Bolarinwa, Abiola Bukunmi
    Hayman, Suzanne
    Abdallah, Nadine
    Binder, Moritz
    Cook, Joselle
    Dispenzieri, Angela
    Dingli, David
    Gertz, Morie A.
    Kourelis, Taxiarchis
    Leung, Nelson
    Lin, Yi
    Muchtar, Eli
    Warsame, Rahma
    Fonder, Amie
    Hobbs, Miriam
    Hwa, Yi Lisa
    Rogers, Michelle
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Kumar, Shaji
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [43] Identification and Molecular Characterization of High-Risk Multiple Myeloma Patients from the MMRF CoMMpass Study at Diagnosis and Progression
    Skerget, Sheri
    Christofferson, Austin
    Nasser, Sara
    Legendre, Christophe
    Yesil, Jennifer
    Auclair, Daniel
    Lonial, Sagar
    Keats, Jonathan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E7 - E7
  • [44] A prognostic gene-signature based identification of high-risk thin melanomas.
    Koelblinger, Peter
    Levesque, Mitchell P.
    Kaufmann, Corina
    Sulberg, Heiko
    Hinke, Axel
    Hoffmann, Marie-Christine
    Brunner, Georg
    Dummer, Reinhard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Identification of patients at high risk of secondary extramedullary multiple myeloma development
    Stork, Martin
    Sevcikova, Sabina
    Minarik, Jiri
    Krhovska, Petra
    Radocha, Jakub
    Pospisilova, Lenka
    Brozova, Lucie
    Jarkovsky, Jiri
    Spicka, Ivan
    Straub, Jan
    Pavlicek, Petr
    Jungova, Alexandra
    Jelinek, Tomas
    Sandecka, Viera
    Maisnar, Vladimir
    Hajek, Roman
    Pour, Ludek
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (04) : 954 - 962
  • [46] Identification of a Gene Signature Associated to Treatment Response to Palbociclib in Multiple Myeloma
    Bruyer, Angelique
    Kassambara, Alboukadel
    Anziani, Paul
    El Bahlagui, Donia
    Robert, Nicolas
    Vincent, Laure
    Klein, Bernard
    Moreaux, Jerome
    BLOOD, 2016, 128 (22)
  • [47] Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
    Richardson, Paul G.
    Sonneveld, Pieter
    Schuster, Michael W.
    Irwin, David
    Stadtmauer, Edward A.
    Facon, Thierry
    Harousseau, Jean-Luc
    Ben-Yehuda, Dina
    Lonial, Sagar
    San Miguel, Jesus-F.
    Cavenagh, Jamie D.
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (05) : 429 - 435
  • [48] Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma
    Naimisha Marneni
    Rajshekhar Chakraborty
    Current Hematologic Malignancy Reports, 2021, 16 : 148 - 161
  • [49] Ultra high-risk myeloma: definition, identification, management
    Avet-Loiseau, Herve
    Minvielle, Stephane
    Moreau, Philippe
    HEMATOLOGIE, 2011, 17 (02): : 145 - 149
  • [50] Real-world Outcomes of Chinese patients with high-risk Multiple Myeloma
    Sui Weiwei
    Deng, Shuhui
    An, Gang
    Xu, Yan
    Hao, Mu
    Mao, Xuehan
    Zou, De-Hui
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E222 - E222
12345